TY - JOUR
T1 - Oral Anticoagulation for Patients With Atrial Fibrillation on Long-Term Hemodialysis
AU - Kuno, Toshiki
AU - Takagi, Hisato
AU - Ando, Tomo
AU - Sugiyama, Takehiro
AU - Miyashita, Satoshi
AU - Valentin, Nelson
AU - Shimada, Yuichi J.
AU - Kodaira, Masaki
AU - Numasawa, Yohei
AU - Briasoulis, Alexandros
AU - Burger, Alfred
AU - Bangalore, Sripal
N1 - Funding Information:
Dr. Shimada is supported in part by unrestricted grants from the American Heart Association National Clinical and Population Research Award and Career Development Award, Honjo International Scholarship Foundation, and Korea Institute of Oriental Medicine. Dr. Bangalore is supported by grants from Abbott Vascular and the National Heart, Lung, and Blood Institute; and is a member of the Advisory Board of Abbott Vascular, Biotronik, Amgen, Pfizer, and Reata. Dr. Burger holds stock in Potola Pharmaceutical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Louise Pilote, MD, MPH, PhD, served as Guest Associate Editor for this paper.
Publisher Copyright:
© 2020 American College of Cardiology Foundation
PY - 2020/1/28
Y1 - 2020/1/28
N2 - Background: Patients on long-term dialysis are at increased risk of bleeding. Although oral anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of stroke, randomized trials have excluded these populations. As such, the net clinical benefit of OACs among patients on dialysis is unknown. Objectives: This study aimed to investigate the efficacy and safety of OACs in patients with AF on long-term dialysis. Methods: MEDLINE and EMBASE were searched through June 10, 2019, for studies that investigated the efficacy and safety of different OAC strategies in patients with AF on long-term dialysis. The efficacy outcomes were ischemic stroke and/or systemic thromboembolism, all-cause mortality, and the safety outcome was major bleeding. Results: This study identified 16 eligible observational studies (N = 71,877) regarding patients on long-term dialysis who had AF. Only 2 of 16 studies investigated direct OACs. Outcomes for dabigatran and rivaroxaban were limited to major bleeding events. Compared with no anticoagulants, apixaban and warfarin were not associated with a significant decrease in stroke and/or systemic thromboembolism (apixaban 5 mg, hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.30 to 1.17; apixaban 2.5 mg, HR: 1.00; 95% CI: 0.52 to 1.93; warfarin, HR: 0.91; 95% CI: 0.72 to 1.16). Apixaban 5 mg was associated with a significantly lower risk of mortality (vs. warfarin, HR: 0.65; 95% CI: 0.45 to 0.93; vs. apixaban 2.5 mg, HR: 0.62; 95% CI: 0.42 to 0.90; vs. no anticoagulant, HR: 0.61; 95% CI: 0.41 to 0.90). Warfarin was associated with a significantly higher risk of major bleeding than apixaban 5 min/2.5 mg and no anticoagulant (vs. apixaban 5 mg, HR: 1.41; 95% CI: 1.07 to 1.88; vs. apixaban 2.5 mg, HR: 1.40; 95% CI: 1.07 to 1.82; vs. no anticoagulant, HR: 1.31; 95% CI: 1.15 to 1.50). Dabigatran and rivaroxaban were also associated with significantly higher risk of major bleeding than apixaban and no anticoagulant. Conclusions: This meta-analysis showed that OACs were not associated with a reduced risk of thromboembolism in patients with AF on long-term dialysis. Warfarin, dabigatran, and rivaroxaban were associated with significantly higher bleeding risk compared with apixaban and no anticoagulant. The benefit-to-risk ratio of OACs in patients with AF on long-term dialysis warrants validation in randomized clinical trials.
AB - Background: Patients on long-term dialysis are at increased risk of bleeding. Although oral anticoagulants (OACs) are recommended for atrial fibrillation (AF) to reduce the risk of stroke, randomized trials have excluded these populations. As such, the net clinical benefit of OACs among patients on dialysis is unknown. Objectives: This study aimed to investigate the efficacy and safety of OACs in patients with AF on long-term dialysis. Methods: MEDLINE and EMBASE were searched through June 10, 2019, for studies that investigated the efficacy and safety of different OAC strategies in patients with AF on long-term dialysis. The efficacy outcomes were ischemic stroke and/or systemic thromboembolism, all-cause mortality, and the safety outcome was major bleeding. Results: This study identified 16 eligible observational studies (N = 71,877) regarding patients on long-term dialysis who had AF. Only 2 of 16 studies investigated direct OACs. Outcomes for dabigatran and rivaroxaban were limited to major bleeding events. Compared with no anticoagulants, apixaban and warfarin were not associated with a significant decrease in stroke and/or systemic thromboembolism (apixaban 5 mg, hazard ratio [HR]: 0.59; 95% confidence interval [CI]: 0.30 to 1.17; apixaban 2.5 mg, HR: 1.00; 95% CI: 0.52 to 1.93; warfarin, HR: 0.91; 95% CI: 0.72 to 1.16). Apixaban 5 mg was associated with a significantly lower risk of mortality (vs. warfarin, HR: 0.65; 95% CI: 0.45 to 0.93; vs. apixaban 2.5 mg, HR: 0.62; 95% CI: 0.42 to 0.90; vs. no anticoagulant, HR: 0.61; 95% CI: 0.41 to 0.90). Warfarin was associated with a significantly higher risk of major bleeding than apixaban 5 min/2.5 mg and no anticoagulant (vs. apixaban 5 mg, HR: 1.41; 95% CI: 1.07 to 1.88; vs. apixaban 2.5 mg, HR: 1.40; 95% CI: 1.07 to 1.82; vs. no anticoagulant, HR: 1.31; 95% CI: 1.15 to 1.50). Dabigatran and rivaroxaban were also associated with significantly higher risk of major bleeding than apixaban and no anticoagulant. Conclusions: This meta-analysis showed that OACs were not associated with a reduced risk of thromboembolism in patients with AF on long-term dialysis. Warfarin, dabigatran, and rivaroxaban were associated with significantly higher bleeding risk compared with apixaban and no anticoagulant. The benefit-to-risk ratio of OACs in patients with AF on long-term dialysis warrants validation in randomized clinical trials.
KW - anticoagulant
KW - atrial fibrillation
KW - dialysis
KW - network meta-analysis
UR - http://www.scopus.com/inward/record.url?scp=85077695196&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077695196&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2019.10.059
DO - 10.1016/j.jacc.2019.10.059
M3 - Article
C2 - 31976865
AN - SCOPUS:85077695196
SN - 0735-1097
VL - 75
SP - 273
EP - 285
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 3
ER -